daraxonrasib
Clinical- Indications
- RAS-addicted cancers
Company intelligence / Profile preview
REV-MED
South Korearevmed.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
REV-MED is a South Korean biotechnology company specializing in the development of innovative technologies for the separation and concentration of blood, bone marrow, and adipose-derived cells. The company aims to advance safe and effective cell therapies within the field of regenerative medicine. Specific clinical results are not publicly disclosed.
- Therapeutic areas
- Dermatology
- Modalities
- Cell therapies (blood, bone marrow, adipose-derived cells)Regenerative medicine platformsPharmaceutical solutions related to cell separation/concentration
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on REV-MED.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REV-MED.